ArticleAmerican journal of translational research2024
Effects of allylestrenol on hormone levels and delivery outcomes in threatened abortion.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of allylestrenol on sex hormone levels and delivery outcomes in women with threatened abortion.
methodsThis retrospective analysis examined clinical data of patients with threatened abortion treated at Huzhou Maternity & Child Health Care Hospital from January 1, 2021, to December 31, 2022. A total of 149 eligible patients were screened and divided into two groups: a control group (n=75) treated with progesterone capsules from January to December 2021, and an observation group (n=74) treated with allylestrenol from January to December 2022. Delivery outcomes, sex hormone levels, complications, and adverse effects were compared between the two groups.
resultsSuccessful delivery was achieved in 62 cases (83.78%) in the observation group and 61 cases (81.33%) in the control group, with no significant difference between the two groups (
conclusionAllylestrenol is comparable to progesterone in improving delivery outcomes for women with threatened abortion, with the added benefits of reducing cesarean section rates and prolonging gestational age, and without increasing safety risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.